RC88, composed of anti-mesothelin mAb and MMAE, is being tested in a phase I clinical trial in mesothelin-positive solid tumor patients, including those with ovarian cancer (Jiang et al., 2021). The gene discussed is MSLN; the disease is ovarian cancer.